Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4,361 GBp
Change Today -5.50 / -0.13%
Volume 1.6M
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 9:33 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Open
4,410 GBp
Previous Close
4,367 GBp
Day High
4,410 GBp
Day Low
4,331 GBp
52 Week High
04/23/15 - 4,906 GBp
52 Week Low
08/14/14 - 4,075 GBp
Market Cap
55.1B
Average Volume 10 Days
2.7M
EPS TTM
1.02 GBp
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
65.4x
Dividend
3.01 GBp
Dividend Yield
4.52%
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZN) Key Developments

AstraZeneca PLC - Special Call

To provide update on progress with company's immuno-oncology pipeline and combination treatments

Astrazeneca and Eli Lilly & Co. Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors

Astrazeneca (AZN) and Eli Lilly & Co. (LLY) said that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA), Eli Lilly's VEGF Receptor 2 antiangiogenic cancer medicine. AstraZeneca's MEDI4736 is a monoclonal antibody developed by MedImmune, the company's global biologics research and development arm, directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. On the other hand, Eli Lilly's ramucirumab is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that specifically binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. The Phase I study, which will assess the combination as a treatment for patients with advanced solid tumors, is expected to establish the safety and a recommended dosing regimen, with the potential to open expansion cohorts in various tumors of interest, for the combination of MEDI4736 and ramucirumab. Under the terms of the agreement, the trial will be sponsored by Lilly. Additional details of the collaboration, including tumor types to be studied and financial terms, were not disclosed.

Amgen Announces Termination of its Co-Development and Commercialisation Agreement with AstraZeneca

Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The announcement follows Amgen's decision to concentrate on other portfolio priorities after observing suicidal ideation and behaviour events in the brodalumab programme which may result in restrictive labelling. AstraZeneca will confirm its decision on the future development of brodalumab as soon as possible, based on further review of the data.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,363.00 GBp -3.50

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €82.95 EUR -1.09
Biogen Inc $389.02 USD -4.33
Celgene Corp $114.11 USD -0.34
Eli Lilly & Co $78.11 USD -0.89
Valeant Pharmaceuticals International Inc C$300.08 CAD 0.00
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 66.1x
Price/Sales 3.3x
Price/Book 5.0x
Price/Cash Flow 66.1x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.